Search research articles
Contact Us
Filters
Showing results (141-150 of 159) with videos related to
Page
of 16
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
June 5, 2024
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma
Jason J Luke, Georgina V Long, Caroline Robert, et al.
European Urology
|
July 17, 2022
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma
Jens Bedke, Brian I Rini, Elizabeth R Plimack, et al.
The New England Journal of Medicine
|
February 18, 2017
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J Vaughn, et al.
The Lancet. Oncology
|
March 15, 2021
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2019
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Y Fradet, J Bellmunt, D J Vaughn, et al.
Nature Medicine
|
August 1, 2025
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial
Brian I Rini, Elizabeth R Plimack, Viktor Stus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2021
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma
David F McDermott, Jae-Lyun Lee, Georg A Bjarnason, et al.
Journal of Geriatric Oncology
|
July 7, 2023
Real-world experience in older patients with diffuse large B-cell lymphoma treated in Latin America: A study by the Latin American study group of lymphoproliferative disorders (GELL)
Myrna Candelaria, Luis Villela, Maria-Alejandra Torres-Viera, et al.
The New England Journal of Medicine
|
February 20, 2019
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I Rini, Elizabeth R Plimack, Viktor Stus, et al.
The Lancet. Oncology
|
March 20, 2025
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial
Thomas Powles, Toni K Choueiri, Laurence Albiges, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 159) with videos related to
Sort By:
Page
of 16
European Journal of Cancer (Oxford, England : 1990)
|
June 5, 2024
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma
Jason J Luke, Georgina V Long, Caroline Robert, et al.
European Urology
|
July 17, 2022
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma
Jens Bedke, Brian I Rini, Elizabeth R Plimack, et al.
The New England Journal of Medicine
|
February 18, 2017
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J Vaughn, et al.
The Lancet. Oncology
|
March 15, 2021
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2019
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Y Fradet, J Bellmunt, D J Vaughn, et al.
Nature Medicine
|
August 1, 2025
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial
Brian I Rini, Elizabeth R Plimack, Viktor Stus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2021
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma
David F McDermott, Jae-Lyun Lee, Georg A Bjarnason, et al.
Journal of Geriatric Oncology
|
July 7, 2023
Real-world experience in older patients with diffuse large B-cell lymphoma treated in Latin America: A study by the Latin American study group of lymphoproliferative disorders (GELL)
Myrna Candelaria, Luis Villela, Maria-Alejandra Torres-Viera, et al.
The New England Journal of Medicine
|
February 20, 2019
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I Rini, Elizabeth R Plimack, Viktor Stus, et al.
The Lancet. Oncology
|
March 20, 2025
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial
Thomas Powles, Toni K Choueiri, Laurence Albiges, et al.
Page
of 16